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Abstract: Recent studies indicated a high prevalence of hyperglycemia in non-diabetic patients presenting with acute 
coronary syndrome (ACS). However, the threshold of admission glucose (AG) as a predictor of adverse events in ACS is 
unclear.
Objective: The aim of this study was to assess the threshold of admission glucose (AG) as a predictor of adverse events 
including Major Acute Cardiac Events (MACE) and mortality, during the ﬁ  rst week of admitting patients presenting 
with ACS.
Material and Methods: The data of 551 patients with ACS were extracted and evaluated. Patients were stratiﬁ  ed according 
to their blood glucose on admission into three groups: group 1:  7 mmol/L (n = 200, 36.3%) and group 2:  7 mmol/L 
and  15 mmol/L (n = 178, 32.3%) and group 3:  15 mmol/L (n = 173, 31.4%). Stress hyperglycemia was arbitrarily deﬁ  ned 
as AG levels   7 mmol/L (group 2 and 3). Patients with ACS were sub-divided into two groups: patients with unstable 
angina (UA, n = 285) and those with ST segment elevation myocardial Infarction (STEMI, n = 266) and data were analyzed 
separately using multiple regression analysis.
Results: The mean age of patients was 59.7 ± 14.8 years and 63% were males. The overall mortality in the population 
was 8.5% (5.4% in STEMI and 3.1% in UA) patients. In STEMI patients, the odds ratio of stress hyperglycemia as 
predictor of mortality in group 3 compared with group 1 was 3.3 (CI 0.99–10.98, P   0.05), while in group 2 com-
pared with group 1 was 2.4 (CI: 0.75–8.07, P = 0.065) after adjustment for age and sex. Similarly, in UA patients, the 
odds ratio of stress hyperglycemia in group 3 compared with group 1 was 2.7 (CI 0.37–18.98, P   0.05), while in 
group 2 compared with group 1 was 2.4 (CI: 0.4–15.2, P = 0.344) after adjustment for age and sex. The incidence of 
more than 2 MACE in both STEMI and UA patients was higher in group 3 compared with the other two groups. 
Regression analysis showed that history of DM, high level of LDL cholesterol, high level of HbA1c, and anterior 
infarction were signiﬁ  cant predictors of adverse events while other risk factors such as BMI, history of hypertension 
and smoking were of no signiﬁ  cance.
Conclusion: This study indicates that the stress hyperglycemia on admission is a powerful predictor of increased major 
adverse events and hospital mortality in patients with acute coronary syndrome.
Keywords: stress hyperglycemia, acute myocardial infarction, glycosylated hemoglobin
Introduction
Admission Hyperglycemia (AG) is commonly associated with marked increase of mortality in 
patients hospitalized with acute coronary syndrome (ACS). Despite the fact that several studies have 
documented this association, hyperglycemia remains underappreciated as a risk factor, and it is 
frequently untreated in ACS patients. This is in large due to the limitations of prior studies regard-
ing the deﬁ  nition of AG and to our understanding of the relationship between hyperglycemia and 
the poor outcomes.
1–3
The predictive value of admission hyperglycemia in acute myocardial infarction whether the patient 
is diabetic or not has been shown to be conﬂ  icting in the previous reports.
4,5 Recent data indicated 
a high prevalence of abnormal glucose metabolism in patients with no history of DM at the time 
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of acute myocardial infarction (AMI), (stress 
hyperglycemia).
6
The level of glycosylated hemoglobin (HbA1c) in 
patients with myocardial infarction reflects the 
glycemic control level within a period of time up to 
120 previous days and was shown to segregate patients 
who had only stress hyperglycemia during acute 
infarction from those who are diabetic
7. So far in the 
setting of ACS, the predictive role of serum level of 
HbA1c as an independent predictor of mortality is not 
clear as it was reported as a useful prognostic marker 
in some reports, but negative by others.
7,8
The ﬁ  rst objective of this retrospective study 
was to deﬁ  ne hyperglycemia on admission and to 
assess the threshold of blood level where it has an 
adverse impact on the outcomes in patients with 
ACS. The second objective was to determine 
whether hyperglycemia on admission (AG) in non 
diabetic patients (stress hyperglycemia) is an inde-
pendent factor for in-hospital mortality in patients 
with ACS or just a surrogate of great severity.
Patients and Methods
Study sample
The data of five hundred and fifty one (551) 
patients who were admitted to the coronary care 
unit (CCU) in Salmaniya Medical Complex in 
Bahrain was extracted from the patients’ ﬁ  les. The 
study had institutional approval.
Inclusion criteria
Patients were eligible for entry in the study if they 
have retrosternal chest pain on rest for more than 
20 minutes with ST segment elevation of more than 
one millimeter in two contiguous leads and two 
fold increment of the cardiac enzymes creatine 
kinase (CK) and CK iso-enzyme (CKMB) classi-
fied as ST elevation myocardial infarction, 
(STEMI) or with ST segment depression without 
increase of cardiac enzymes, (classiﬁ  ed as Unsta-
ble angina (UA). The data of all patients admitted 
to the CCU that ﬁ  t the inclusion criteria were 
extracted over the duration of 12 months (from 
beginning of January to end of December 2005).
Exclusion criteria
Patients were excluded if they had history of severe 
heart failure or if they had history of deﬁ  nite myo-
cardial infarction in the past.
Clinical and biochemical data
Patients’ data of age, sex, body mass index, history 
of diabetes mellitus, hypertension, smoking and 
hyperlipidemia (LDL   3.9 mmol/L) were all 
extracted. Serum levels of the following parameters 
were tabulated: Serum admission glucose (AG), 
glycosylated haemoglobin (HbA1c), low density 
lipoprotein (LDL) cholesterol and total creatine 
kinase as previously reported.
9
Patients were stratiﬁ  ed according to their blood 
glucose on admission into three groups as shown 
in Figure 1 Group 1 (control):  7 mmol/L (n = 200, 
36.3%) and group 2:  7 mmol/L and  15 mmol/L 
(n = 178, 32.3%) and group 3:  15 mmol/L (n = 173, 
31.4%). Stress hyperglycemia was arbitrarily 
deﬁ  ned for AG levels  7 mmol/L (group 2 and 3, 
n = 351, 63.7%). Patients with ACS were sub-
divided into two groups: patients with unstable 
angina (UA, n = 285) and those with ST seg-
ment elevation myocardial Infarction (STEMI, 
n = 266).
The level of HbA1c of more than 6.5% was 
regarded high and indicative of DM in the past 
even if patient was not aware of it. Thrombolytic 
therapy in STEMI patients and other medications 
given were recorded. The frequency of using 
different medications during hospitalization in 
all groups were matched for oral aspirin, oral 
clopidogrel, intravenous heparin, subcutaneous 
low molecular weight heparin, beta blockers, 
angiotensin receptor antagonists, and intravenous 
nitroglycerine.
Outcomes
Events such as death or Major Acute Cardiac 
Events (MACE) such as signiﬁ  cant arrhythmias 
(supra ventricular tachycardia, atrial ﬁ  brillation, 
ventricular tachycardia or ventricular ﬁ  brillation), 
pulmonary edema, hypotension (if systolic pres-
sure is less than 90 mmHg) or cardiogenic shock 
were all extracted and tabulated in groups accord-
ing to plasma AG level on admission as mentioned 
above.
Twelve leads ecg
The site of myocardial infarction on 12 leads ECG 
was analyzed. ST segment elevation at leads 
V1–V4 represented anteroseptal infarction, at 
leads II, III, aVF represented inferior infarction 
and at leads I, aVL, V5, V6 represented lateral 
infarction.31
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Statistical analysis
The extracted data of the patients were entered 
and analyzed using the Statistical Package for 
Social Sciences program (SPSS version 15.0). 
Relevant descriptive statistics were computed for 
all study variables. One-way analysis of variance 
(ANOVA) was used to compare the means of the 
quantitative variables (LDL, Hb, creatinine, BMI 
and age) across the three groups based on serum 
level of AG. Post hoc analysis was used for mul-
tiple comparisons. The association between the 
groups of AG and each of the study qualitative 
variables such as: history of smoking, history of 
DM, history of hypertension, gender and MACE 
was tested using the Chi-square test of indepen-
dence. The multiple logistic regression analysis 
was used to predict the probability of death using 
the following predictors Serum level of AG, 
HbA1C, LDL level, BMI, history of hypertension, 
DM, or smoking and the site of myocardial infarc-
tion. The odds ratios with the conﬁ  dence intervals 
(CI) were calculated for all variables. Any analy-
sis with p-value less than 0.05 was considered 
statistically signiﬁ  cant.
Results
The data of 551 patients was evaluated in the study. 
Fifty one percent had myocardial infarction (STEMI, 
n = 285), and 49% had unstable angina (UA, 
n = 266) with no infarction. Three hundred and ﬁ  fty 
one patients (63.7%) were hyperglycemic with AG 
more than 7 mmol/L and 200 (36.3%) were normo-
glycemic with AG less than 7 mmol/L.
Among the hyperglycemic patients, 186 (33.8%) 
had DM and, 186 (33.8%) had no DM, 271(49%) 
had history of hypertension and 211 (38.2%) had 
history of smoking.
Table 1 shows the demographic and biochemical 
data of the study population. The mean age was 
59.7 ± 14.8 years (range 24–88), with 348 males 
(63%). There were no significant differences 
between males and females in relation to the level 
of AG, serum creatinine, level of hemoglobin and 
body mass index.
The LDL level and the HbA1c level were match-
ing in each subgroup with increment at group 2 and 
3 compared to group 1 in SEMI and in UA groups. 
Multiple comparison results show that the mean 
level of total CK was signiﬁ  cantly higher in group 3 
compared to group 1, and group 3 versus group 2 
(p   0.001 in each).
The mean HbA1c was signiﬁ  cantly lower in 
group 1 compared with that of groups 2 and 3 
(p   0.001 in each). The mean age of group 3 was 
signiﬁ  cantly higher than that of group 2 (p = 0.027). 
The serum LDL level for the three groups were 
signiﬁ  cantly different (p   0.001 in each).
In STEMI group, 80/112 (72%) of patients in 
group 1, 60 out of 88 (69%) patients in group 2 
Stress Hyperglycemia
≥
Control Stress Hyperglycemia
Study population
(n = 551)
According to Admission Glucose According to Diagnosis
≤7 mmol/L
(n = 200)
>7 & <15 mmol/L
(n = 178)
≥15 mmol/L
(n = 173)
Unstable Angina
(n = 285)
STEMI
(n = 266)
Figure 1. Distribution of the population groups in the study.32
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and 59 out of 85 (70%) in group 3 were given 
thrombolytic therapy.
The site of AMI on 12 leads ECG in STEMI 
group was anterior in 50%, 52% and 54% of 
patients in group 1, 2, 3 respectively and was infe-
rior in 31%, 33% and 27% of the patients in the 
three groups, respectively. The sites of AMI were 
evaluated among those who died, it was observed 
that the site was anterior MI in 22/30 patient (73%), 
inferior lateral in 4 (13%) and inferior with right 
ventricular infarction in 4 (13%).
In-hospital outcomes
Major acute cardiac events (mace) 
in stemi patients
Figure (2) shows the frequency of  MACE in the three 
groups in STEMI and UA patients. The number of 
patients with STEMI who had more than two MACE 
were, 59 (67% and 16 (17%), 12 (8%) in groups 3, 
2 and 1, respectively. In unstable angina, patients who 
had more than 2 MACE were 36 (36%), 11(12%) 
and 8 (7%) in groups 3, 2 and 1, respectively.
Mortality in STEMI patients
Overall mortality in the population was 47/552 
(8.5%), where 30/552 (5.4%) in STEMI and 17/552 
(3.1%) in UA. In the STEMI patients, the total death 
was 30: twelve patients (4.2%) were in group 3, 
eleven patients (3.9%) in group 2 and seven (2.4%) 
in group 1. In UA patients the total death were 
17 out of 266, nine patients (3.3%) in group 3, six 
patients (2.2%) in group 2 and two in group 1 
(0.7%), respectively.
Table 2 shows the results of multivariate regres-
sion analysis for predictors of mortality in the study 
population. In STEMI group, the odds ratio of 
serum level AG, Hb A1C, and LDL were signiﬁ  cant   
(p   0.05), the odds ratio of the anterior MI 
(not shown in Table) on 12 leads ECG was 2.7 (CI: 
0.5–13, p   0.001), the odds ratio for inferior AMI 
and other sites were not signiﬁ  cant. The stress 
hyperglycemia, level of LDL, serum level of 
HbA1c and anterior AMI on ECG were signiﬁ  cant 
predictors of adverse events. The BMI, history of 
hypertension and smoking on admission were not 
signiﬁ  cant. The odds ratio of serum level of HbA1c 
as a predictor of mortality in the whole study was 
1.4 (CI: 0.5–1.9, p-value = 0.04) in the hypergly-
cemia patients.
Table 3 shows the predictive value of stress 
hyperglycemia and D.M. for mortality in groups 3 
and 2 compared with group 1 after adjusting for age 
and gender. In stress hyperglycemia, the odds ratio 
of mortality in group 3 compared to group 1 was 3.3 
(CI: 0.99–10.98, p   0.05) in STEMI patients and 
0
10
20
30
40
50
60
70
STEMI (n = 285)
Group 1
Group 2
Group 3
UA (n = 266)
Figure 2. The number of patients who had more than two major acute cardiac events (MACE) in the study population. Group 1: control group 
with glucose  7 mmol/L, Group 2: admission glucose 7− 15 mmol/L and Group 3: admission glucose  15 mmol/L.34
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2.7 for UA (CI: 0.3–17.4, p   0.05). In group 2 
compared to group 1, the odds ratio were not sig-
niﬁ  cant for neither STEMI of 2.4 (CI: 075–8.07, 
P = 0.318) nor for UA of 2.4 (CI: 0.37–15.2, 
p = 0.34).
In hyperglycemia with history of DM, the odds 
ratio were signiﬁ  cant in group 3 in STEMI in com-
parison to group 1, were of no signiﬁ  cance in UA.
The odds ratio for death was noted to be pro-
gressively increased with a higher level of AG.
Discussion
This study demonstrates that stress hyperglycemia 
on admission in the absence of DM is a signiﬁ  cant 
predictor of adverse outcome in patients presenting 
with ACS. We have also demonstrated that serum 
level of HbA1c and anterior AMI on ECG are 
significant predictors of adverse outcome in 
patients presenting with ACS. However, BMI, level 
of LDL, history of hypertension and smoking on 
admission were not significant predictors of 
adverse outcome.
In the current study population, the incidence 
of stress hyperglycemia was 33%, which is lower 
than previous reports of 48% and 54%.
10,11 Those 
who had hyperglycemia and DM were 29%. The 
incidence of hyperglycemia with DM varies in 
different studies between 23%–41%.
12,13 Thirty 
two percent had history of hypertension, which is 
higher than those previously reported (28% and 
25%) in other studies, respectively.
14,15
The unique finding in this study is that we 
demonstrated the relationship between adverse 
events in ACS patients and admission glucose based 
Table 2.  Multiple logistic regression analysis results for the prediction of death in groups with hyperglycemia against 
group 1 after adjusting for age, gender and history of DM. 
Group according 
to Admission glucose
STEMI group UA group
Variable Odds ratio Conﬁ  dence 
interval
p-value Odds ratio CI p-value
Admission glucose 2.8 0.7–11.3 0.03 2.8 0.8–10.8 0.02
HbA1c 1.4 0.5–1.9 0.04 0.96 0.7–1.2 0.03
History of smoking 0.5 0.2–1.5 0.27 0.71 0.2–2.8 0.56
History of 
Hypertension
0.8 0.3–1.6 0.35 1.3 0.4–4.3 0.65
BMI 1.01 0.9–1.1 0.77 0.9 0.78–1.08 0.313
LDL level 1.01 0.7–1.1 0.03 0.99 0.4–1.4 0.04
Abbreviations: STEMI, ST segment elevation myocardial infarction; UA, unstable angina; HBAC, Glycosylated hemoglobin C; BMI, body 
mass index.
Table 3. The odds ratio of deaths in patients with stress hyperglycemia with no history of DM on admission and 
hyperglycemia with history of DM.
Parameter Group 2 versus 1 Group 3 versus 1
Odd ratio C I p-value Odds ratio C I p-value
STEMI
with stress 
hyperglycemia
2.4 0.75–8.07 0.318 3.3 0.99–10.98 0.04
with history 
of DM
3.1 0.94–8.07 0.06 3.2 0.99–10.98 0.03
UA
with stress 
hyperglycemia
2.4 0.4–15.2 0.34 2.7 0.37–18 0.02
With history 
of DM
2.7 0.4–173 0.28 4.5 0.3–25.7 0.0835
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on a unique classiﬁ  cation of stress hyperglycemia. 
The stratiﬁ  cation for the hyperglycemia was based 
on AG at two levels, group 2 between 7 and 
15 mmol/L, and group 3 is more than 15 mmol/L, 
whereas AG less than 7 mmol/L was regarded as 
normoglycemia. In some other studies, however, 
clinical analysis for outcome was based on AG level 
below or above 9.4 mmol/L.
16 In two other studies, 
the patients data were analyzed based on the normal 
level of  6.8 mmol/L and above 11 mmol/L, and 
the in-between of 6.8 to 11 mmol/L.
17,18 The 
differences in selecting the cutoff for the stress 
hyperglycemia between the current study and others 
appear to be related to the research question raised 
in each study. The stratiﬁ  cation in our study was 
arbitrarily selected with the aim of assessing the 
threshold of the AG level and its relationship with 
adverse outcome in ACS patients.
In ACS patients with stress hyperglycemia, the 
odds ratio of in-hospital mortality was signiﬁ  cantly 
higher in group 3, compared with group 1 in 
STEMI and in UA patients. Also in group 2, the 
odds of mortality were higher but with no signiﬁ  -
cance compared with group 1 for STEMI and UA 
patients. This was in keeping with many other trials 
that showed stress hyperglycemia as a predictor of 
in hospital mortality.
19,20 The cardiac events of 
more than two per patient were higher in group 3 
and group 2 compared with group 1 in both STEMI 
and UA patients. This is in agreement with a previ-
ous report showing that cardiac failure was 
signiﬁ  cantly higher among those with high level 
of AG on admission.
21,22 Another study have also 
demonstrated that the relative risk of congestive 
cardiac failure in AMI with stress hyperglycemia 
had increased risk of death with relative risk of 1.7 
(CI: 1.2–2.4).
21,22
In STEMI patients, the level of the cardiac 
enzyme creatine kinase were signiﬁ  cantly higher 
in group 3 compared to group 1, indicating a larger 
myocardial infarction in that group. It is not known 
whether this was the cause or the result of high AG. 
The rate of anterior AMI was high among those 
who died (73%). In one report, the high level of 
total CK was associated with high level of glucose 
and that the site of anterior MI was an independent 
predictor for high in-hospital complications in AMI 
patients.
15 Patients with stress hyperglycemia in 
this study had a similar and signiﬁ  cant predictive 
odds ratio for mortality compared with patients 
with DM in STEMI patient and UA patients when 
the level of AG   15 mmol/L. Previous reports 
have shown that hyperglycemia on admission with 
history of DM is a useful predictor of short and 
long-term morbidity and mortality.
24,25
The exact mechanism of the high predictive 
value of stress hyperglycemia on admission for 
adverse outcome in ACS is not known. However 
this could be due to high adrenergic drive in ACS 
during myocardial ischemia.
24 Many previous 
experimental and human studies showed that the 
ischemic preconditioning, which is a protective 
mechanism against myocardial injury on exposure 
to ischemia is blunted or abolished completely in 
linear relation with the level of glucose.
25 The high 
level of AG has recently been linked to a greater 
tendency for local thrombin generation and plate-
let activation and unfavorably altered clot features 
in patients with ACS.
26 An alternative approach in 
discussion is that stress hyperglycemia could be a 
consequence of the ACS. The cause of stress hyper-
glycemia in ACS could be due to increased activity 
of neurohormonal pathways such as catechol-
amines, cortisol and growth hormone which 
produce signiﬁ  cant insulin resistance.
27 The activa-
tion of circulating cytokines such as tumor necrosis 
factor-α may lead to reduction of insulin sensitivity, 
thus increase serum level of glucose.
28,29 Investi-
gating a cause and effect relationship between 
stress hyperglycemia and ACS requires other future 
studies with different design.
High level of glycosylated hemoglobin in this 
study was shown to be an independent predictor of 
adverse outcome in the setting of acute myocardial 
infarction which is in agreement with others
7,8 but 
differs with Timmer et al. where HbA1c was of no 
predictive value for mortality or morbidity in ACS 
patients.
11 It was presumed that high level of 
HbA1c is a leading cause of endothelial dysfunction 
and impairment of the mechanism for the release 
of ischemia mediators.
30
Among other factors that was found to be of 
adverse predictive value on regression analysis 
was the anterior MI, and the history DM. History 
of hypertension on admission as a predictor of 
mortality in STEMI was not a significant, 
similar ﬁ  nding was reported previously.
31 The 
mean of the body mass index was not elevated 
indicating the obesity was not noted in the study 
group and the odds of BMI were not signiﬁ  cant as 
a predictor of poor outcome. However in one study 
it was shown high BMI on admission is related 
positively to occurrence of ACS in patients with 
well established coronary artery disease.
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Limitations of the Study
The retrospective nature of the study and the short-
term outcome measurements could be considered 
as limitations in the current study.
Conclusion
Multivariate logistic regression analysis in this 
study showed that the stress hyperglycemia on 
admission is a powerful predictor of in-hospital 
mortality in patients with acute ST segment eleva-
tion myocardial infarction and unstable angina, 
particularly when the level of AG is   15 mmol/L. 
The history of DM, the site of anterior MI on ECG, 
high LDL cholesterol and high level HbA1c were 
all useful predictors of adverse outcome. However, 
the history of smoking, history of hypertension and 
Body mass index on admission were not useful 
predictors of adverse outcome in ACS.
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